CIK 0001422143
- Non-accelerated filer
- Smaller reporting company
Kura Oncology, Inc.
Sign in to watch- Ticker
- KURA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 611547851
- Phone
- +1 858-500-8800
- Business address
- 4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA, 92121
- Former names
- ZETA ACQUISITION CORP III
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Planned sale Chief Operating Officer sold 526 shares at $16.03 ($8,434)
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Planned sale Chief Legal Officer sold 2,615 shares at $22.15 ($57,916)
- 4 Open-market sale SVP, Finance & Accounting sold 2,318 shares at $17.80 ($41,262)
- 4 Open-market sale Chief Legal Officer sold 2,053 shares at $17.80 ($36,544)
- 4 Open-market sale Chief Operating Officer sold 1,496 shares at $17.80 ($26,630)
- 4 Open-market sale Chief Medical Officer sold 11,983 shares at an average $19.31 ($231,396)
- 4 Open-market sale President and CEO sold 91,052 shares at $20.23 ($1,841,982)
- 4 Grant or award SVP, Finance & Accounting acquired 21,250 shares (grant or award)
- 4 Grant or award Chief Commercial Officer acquired 15,000 shares (grant or award)
- 4 Derivatives Options or other derivatives
Page 5 of 14 · 277 filings